• Bivalent mRNA covid-19 vaccines that also target the Omicron variant: more antibodies (December 2022) > HERE
   
• Messenger RNA covid-19 vaccines: an update on adverse effects (November 2022) > HERE
   
• Viral vector covid-19 vaccines authorised in the European Union: a review of their adverse effects  (October 2022) > HERE
   
• An African covid-19 vaccine, despite foot-dragging by drug companies  (October 2022) > HERE
   
• Tixagevimab + cilgavimab (Evusheld°) in the prevention of covid-19 > Pdf, subscribers only
   
• Covid-19: delays in other types of health care (July 2022) > HERE
   
• Nirmatrelvir + ritonavir (Paxlovid°) in covid-19, for certain patients at risk of developing severe disease (June 2022) > HERE
   
• Messenger RNA covid-19 vaccines tozinameran (Comirnaty°) and elasomeran (Spikevax°) during pregnancy (June 2022) > HERE
  
  
• NVX-CoV2373 (Nuvaxovid°) in the prevention of covid-19 in adults. Effective for at least 3 months, but no proven efficacy against the Omicron variant (June 2022) > Pdf, subscribers only
   
• Casirivimab + imdevimab (Ronapreve°) in early covid-19 (May 2022) > Pdf, subscribers only
  
  
• Molnupiravir (Lagevrio°) in early covid-19 (May 2022) > Pdf, subscribers only
   
• Tozinameran (Comirnaty°) and covid-19 in adolescents (April 2022) > Pdf, subscribers only
  
  
• Tozinameran (Comirnaty°) and covid-19 from 5 to 11 years of age (April 2022) > Pdf, subscribers only
   
• Elasomeran (Spikevax°) and covid-19 in adolescents (April 2022) > Pdf, subscribers only
  
  
• Colchicine and covid-19 warranting hospitalisation: not worth the risk (April 2022) > Pdf, subscribers only
   
• "Covid-19 vaccine booster dose: demonstrated clinical efficacy during Delta variant predominance, and no new safety signals" (March 2022) > Pdf, subscribers only
   
• "Molnupiravir and early covid-19 without signs of severe illness: value uncertain, including in unvaccinated patients at risk of exacerbation" (March 2022) > Pdf, subscribers only
   
• "Update on myocarditis linked to the covid-19 messenger RNA vaccines tozinameran (Comirnaty°) and elasomeran (Spikevax°)" (February 2022) > HERE
  
  
• "Covid-19 vaccines : good for business too" (February 2022) > HERE
   
• "Casirivimab + imdevimab (Ronapreve°) in early covid-19 with no signs of severity: possibly useful in patients at high risk of developing severe covid-19" (January 2022) > Pdf, subscribers only
   
• Covid-19 vaccine booster dose: great uncertainty over its value in the general population (November 2021) > HERE
   
• Known Adverse effects of messenger RNA covid-19 vaccines as of mid-2021 (November 2021) > HERE
   
• "The Sars-CoV-2 Delta variant: how effective are covid-19 vaccines against this strain?" (October 2021) > HERE
  
  
• "Covid-19 vaccines: glaring inequality" (October 2021) > HERE
   
• "Viral vector covid-19 vaccine ChAdOx1-S (Vaxzevria°) and covid-19. Efficacy in the short term, but a risk of rare, sometimes fatal, thrombosis" (September 2021) > HERE
   
• "Covid-19 drugs and vaccines: big money and winning alliances" (June 2021) > HERE
   
• "Waste in covid-19 clinical trials" (June 2021) > HERE
    
• "Covid-19 vaccine Ad26.CoV2S (by Janssen): as with the other covid-19 vaccines, effective in the short term but unknowns remain" (23 March 2021) > HERE
   
• "The AstraZeneca covid-19 vaccine: British epidemiological data on the vaccination of older adults, and reassuring pharmacovigilance data" (15 March 2021) > HERE
  
  
• "Messenger RNA covid-19 vaccines: Prescrire's in-depth analysis as of end February 2021 (2 March 2021) > HERE
  
  
• "Covid-19 and ivermectin: many trials, few results, no proven efficacy " (13 February 2021) > HERE
  
  
• "The ChAdOx1 nCoV-19 covid-19 vaccine from AstraZeneca: great uncertainty over its efficacy" (29 January 2021) > HERE
  
  
• "The covid-19 messenger RNA vaccine from Moderna: as with the tozinameran vaccine (Comirnaty°, Pfizer/BioNTech), limited data and unanswered questions" (6 January 2021) > HERE
   
• "The covid-19 messenger RNA vaccine tozinameran (Comirnaty°, from Pfizer and BioNTech) in elderly patients: limited data, many uncertainties" (23 December 2020) > HERE
   
• "Covid-19 and vitamin D: too uncertain" (15 December 2020) > HERE
   
• "Evaluation of covid-19 vaccines: the questions to ask" (20 November 2020) > HERE
   
• "Covid-19 patients who are not hospitalised: anticoagulation is rarely justified" (24 September 2020) > HERE
   
  
• "Proton pump inhibitors: increased risk of severe covid-19" (15 September 2020) > HERE
   
• "Hydroxychloroquine in covid-19: no proven efficacy, including in less severe forms of the disease" (24 July 2020) > HERE
   
• "Covid-19: remdesivir (Veklury°) authorised in the European Union, yet much remains unknown or uncertain" (13 July 2020) > HERE
   
• "Covid-19 and severe breathing problems: dexamethasone reduced mortality in one trial" (24 June 2020) > HERE
   
• "Lack of access to drug evaluation data: a recurrent problem, not confined to covid-19" (8 June 2020) > HERE
   
• "Covid-19 and hydroxychloroquine (Plaquenil°): new data show no evidence of efficacy"  (16 April 2020) > HERE
   
• "New data on the cardiac adverse effects of the combination of hydroxychloroquine (Plaquenil°) with azithromycin (Zithromax° or other brands)" (16 April 2020) > HERE
  
  
• "Covid-19 and hydroxychloroquine (Plaquenil°): still no conclusive results" (15 April 2020) > HERE
  
  
• "Covid-19 and hydroxychloroquine: uncertainties and unanswered questions" (2 April 2020) > HERE
  
  
• "Covid-19 and hydroxychloroquine: caution" (30 March 2020) > HERE
   
• "Covid-19 and drug trials: what to make of the initial results?" (23 March 2020) > HERE
  
  
• For more information in French, see www.prescrire.org:
  > Covid-19. Année 2022. Des informations fiables et utiles
  
  

For more updates, follow us on Facebook and Twitter

Keep up with the latest from Prescrire's editors, and support our values of independence and quality information, first and foremost in the interest of patients. > Follow us on Facebook or > Follow us on Twitter